This document discusses cholinesterase inhibitors, which prevent the breakdown of acetylcholine and butyrylcholine neurotransmitters. It covers their classification into natural alkaloids, semisynthetic derivatives, and synthetic compounds. Cholinesterase inhibitors increase levels of acetylcholine and butyrylcholine in the synaptic cleft by inhibiting the acetylcholinesterase enzyme. Their therapeutic uses include treatment of glaucoma, Alzheimer's disease, myasthenia gravis, cobra bites, and belladonna poisoning. Common adverse drug reactions are nausea, increased salivation, flushing, and bronchospasm.